Insmed Investment and other (expense) income, net decreased by 21.0% to $12.04M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 13.4%, from $13.91M to $12.04M. Over 4 years (FY 2021 to FY 2025), Investment and other (expense) income, net shows an upward trend with a 332.1% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Positive values indicate effective treasury management or successful non-core investments, while negative values may indicate financial costs or investment losses.
This captures income or expenses derived from non-core activities, such as interest income, investment returns, or other...
Standard non-operating line item; comparable across most corporate entities.
other_investment_income_nonoperating| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $34.00K | $46.00K | $61.00K | $137.00K | $835.00K | $1.79M | $8.32M | $10.52M | $11.17M | $10.58M | $9.85M | $8.78M | $10.29M | $16.98M | $17.26M | $13.91M | $13.23M | $18.29M | $15.24M | $12.04M |
| QoQ Change | — | +35.3% | +32.6% | +124.6% | +509.5% | +114.5% | +364.4% | +26.5% | +6.2% | -5.3% | -6.9% | -10.9% | +17.1% | +65.1% | +1.6% | -19.4% | -4.9% | +38.3% | -16.7% | -21.0% |
| YoY Change | — | — | — | — | >999% | >999% | >999% | >999% | >999% | +490.9% | +18.5% | -16.5% | -7.9% | +60.5% | +75.1% | +58.3% | +28.6% | +7.7% | -11.7% | -13.4% |
| Segment | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 |
|---|---|---|---|---|---|---|---|---|
| Reportable Segment | $2.77M | $10.53M | $10.53M | $10.53M | $10.53M | -$8.78M | -$10.29M | $16.98M |
| Total | $8.32M | $10.52M | $11.17M | $10.58M | $9.85M | $8.78M | $10.29M | $16.98M |